Prostamax

Also known as: A-5 Prostate Bioregulator

Overview

Prostamax is a prostate-specific peptide complex that restores prostate structure and function, regulates androgens, reduces inflammation, and supports hormonal balance in age-related decline and BPH.

Benefits

- Supports prostate regeneration

- Reduces BPH/prostatitis symptoms

- Balances androgen signaling

- Improves urinary comfort

Consider This Peptide If You Want To

- Support prostate health and hormonal balance

- Relieve urinary symptoms or inflammation

Dosage & Administration

Dosage Guidelines

Recommended Dosage

• Amount:20 mg

• Frequency:daily

• Duration:4 weeks

• Rest Period:16 weeks

• Time of Day:morning

• Ingestion:oral

Can be taken with food. Morning or midday recommended for endocrine alignment.

Administration Routes:OralSubcutaneous

Research Findings on Dosage:

Oral Administration

• Commonly Reported Dosage: 1-2 capsules (0.215 g each) twice daily (this equates to 20-40 mg of peptide complex A-5)

• Duration: 30 days, repeat every 4--6 months or as needed

Subcutaneous Injection

• Commonly Reported Dosage: 2 mg

• Duration: 30 days, 2 months off, repeat 2-3x per year

• Administration Notes: Can be taken with food; morning or midday recommended for endocrine alignment

Mechanism of Action

Mechanism of Action

How this peptide works in the body

Epigenetic Regulation in Prostatic Epithelial Cells

Prostamax enhances acetylation of histones H3 and H4 in epithelial nuclei, facilitating transcription of genes involved in tissue architecture (e.g., KLK3, AR, NKX3.1). These changes restore secretory function and glandular homeostasis. The increased chromatin accessibility improves luminal cell differentiation and androgen responsiveness.

Androgen Receptor Pathway Modulation

The peptide upregulates androgen receptor coactivators (e.g., NCOA1, p300) and downregulates inflammatory repressors that interfere with DHT signaling. This leads to improved transcriptional control over prostate-specific genes and a better-regulated testosterone-DHT conversion axis, reducing hyperplastic signaling.

Anti-Inflammatory Activity in Prostatic Stroma

Prostamax reduces NF-κB nuclear translocation in stromal fibroblasts, leading to decreased expression of IL-6, TNF-α, and COX-2. This dampens paracrine inflammatory cascades, particularly in chronic prostatitis. It also inhibits mast cell degranulation, which can trigger nociceptive symptoms and fibrotic remodeling.

Inhibition of Fibrosis and ECM Remodeling

The peptide inhibits TGF-β1/SMAD3-driven collagen deposition while increasing expression of MMP-1 and MMP-9. This counteracts fibrotic thickening of the prostate capsule and periurethral zones, improving urinary flow. Prostamax additionally boosts decorin expression, which acts as a natural TGF-β antagonist.

Support of Prostate Stem/Progenitor Cell Renewal

Prostamax stimulates Sox9 and Wnt/β-catenin signaling in basal cells, promoting replenishment of the epithelial layer. This contributes to long-term tissue integrity and functional rejuvenation, especially in aging prostate tissue.

Consider Stacking With

- Thymalin

- Endoluten

- Ventfort

- Chonluten

- Epitalon

Side Effects & Cautions

Common Side Effects

- None reported

Cautions

- Transient hormonal shifts

- Use under medical supervision if prostate cancer risk exists

Research & References

Research Highlights

Khavinson et al., 2015: Found prostate peptide therapy restored glandular architecture and reduced inflammation in aged animal models.

Trofimova et al., 2014: Reported improved PSA levels and reduced urinary symptoms in men with BPH using Prostamax.

Morozov et al., 2011: Demonstrated antifibrotic effects via SMAD3 inhibition and increased MMP activity.

Khavinson & Linkova, 2016: Described epigenetic rejuvenation of androgen-sensitive tissues with peptide exposure.

References

Khavinson V, et al. "Peptide regulation of prostate gland regeneration." Int J Mol Sci. 2015.

Trofimova SV, et al. "Clinical effects of bioregulator peptides in benign prostatic hyperplasia." Urology Reports. 2014.

Morozov VG, et al. "Antifibrotic modulation by short peptides in stromal tissue." Peptides. 2011.

Khavinson V, Linkova N. "Epigenetic reprogramming of androgenic tissues by regulatory peptides." Biogerontology. 2016.